

Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis

NCT06940661

Status	RECRUITING
Phase	Phase 2
Sponsor	Assistance Publique - Hôpitaux de Paris
Enrollment	33 participants

Key Eligibility Criteria

Inclusion (5)

- Patient aged of 18 years or older,
- Patients with relapsing granulomatosis with polyangiitis positive for PR3-ANCA at inclusion according to the ACR/EULAR 2022 classification criteria, and/or the 2012 revised Chapel Hill Consensus Conference definition.
- Patients with an active disease defined as a Birmingham Vasculitis Activity Score (BVAS) ≥ 3 ,
- Patients within the first 21 days following initiation/increase of glucocorticoids at a dose ≥ 1 mg/kg/day (pulses of methylprednisolone before oral glucocorticoid therapy are authorized)
- Patient able to give written informed consent prior to participation in the study, - Affiliation with a mode of social security (profit or being entitled).

Exclusion (21)

- Patients with MPO-positive AAV, or other vasculitis, defined by the ACR criteria and/or the Chapel Hill Consensus Conference,
 - Patients with vasculitis in remission of the disease defined as a BVAS < 3 ,
 - Patients with a newly-diagnosis of GPA
 - Patients treated with rituximab within the last 6 months before inclusion
 - Patients treated with cyclophosphamide within the last 6 months before inclusion
- ... and 16 more (see full listing online)

Locations (1 total)

Service de Médecine Interne, Centre de référence "Maladies systémiques et autoimmunes rares, en particulier Vasculites nécrosantes et Sclérodermies systémiques", Paris, France